The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with a 3.69% annual growth rate, according ...

GI comedication usage was less with rofecoxib than with NSAIDs for each type of medication. The proportions of patients having GI endoscopies were also less with rofecoxib vs NSAIDs, while the ...

Context: Patients treated with nonselective cyclooxygenase inhibitors (nonsteroidal anti-inflammatory drugs [NSAIDs]) often experience dyspepsia and upper gastrointestinal (GI) adverse effects ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

“Ultimately, our hope is to have a product that is free of bacteria and potentially harmful viruses, leaving only a purified dose of good viruses, called bacteriophages, that can potentially fight ...

According to Trilliant’s report, GLP-1s could boost or bring down demand for other medical treatments like gastrointestinal (GI) medications and bariatric surgeries.

The following is a summary of “Brain Fog in Gastrointestinal Disorders: Small Intestinal Bacterial Overgrowth, Gastroparesis, ...